Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use
The present disclosure relates to crystalline solids comprising a compound of Formula (I), wherein R is n-propyl, and methods of making compounds of Formula (I) wherein R is C1-C4 alkyl or C2-C4 alkenyl. The present disclosure also relates to crystalline solids comprising a compound of Formula (II), The present disclosure further relates to methods of preparing the crystalline solids, and pharmaceutical preparations of the crystalline solids, and use of such pharmaceutical preparations in treatment of diseases and conditions.
1. A crystalline solid comprising a compound of Formula (II),
(II), having 2θ values 21.5, 24.2, 26.7, and 19.6.
2. The crystalline solid of claim 1 , wherein the compound of Formula (II) is a hydrate.
3. The crystalline solid of claim 1 , wherein said crystalline solid contains residual non-solvated solvent or residual non-hydrated water.
4. The crystalline solid of claim 1 , comprising less than about 5% by weight nicotinic acid.
5. The crystalline solid of claim 1 , comprising less than about 1% nicotinic acid riboside.
6. The crystalline solid of claim 1 , comprising at least about 90% of the compound of Formula (II).
7. A composition comprising a crystalline solid of claim 1 and one or more pharmaceutically acceptable excipients.
8. A method for preparing a crystalline solid of claim 1 , comprising:
a) dissolving the compound of Formula (II) in a solvent to form a solution; and
b) crystallizing the compound of Formula (II) from the solution to form the crystalline solid, wherein the solvent comprises water.
9. The method of claim 8 , wherein the solvent further comprises an alcohol.
10. The method of claim 9 , wherein the alcohol is 1-propanol.
11. The method of claim 8 , wherein the temperature of the solvent during the dissolving step is ambient temperature.
12. The method of claim 8 , wherein crystallizing comprises forming a supersaturated solution from the solution, wherein the supersaturated solution is supersaturated with respect to the compound of Formula (II).
13. The method of claim 12 , wherein forming the supersaturated solution comprises adding an anti-solvent to the solution, lowering the temperature of the solution, reducing the volume of the solution, or any combination thereof.
14. The method of claim 8 , wherein crystallizing comprises adding a seed crystal to the solution, wherein the seed crystal comprises the compound of Formula (II).
15. A method of increasing NAD levels in a subject, the method comprising administering a crystalline solid according to claim 1 to the subject.
16. A method of treating or preventing a disease or disorder in a subject, the method comprising administering a crystalline solid according to claim 1 to the subject.
17. A method of purifying a compound of Formula II:
said method comprising:
a) dissolving a solid comprising a compound of Formula (II) in a solvent to form a solution; and
b) crystallizing the compound of Formula (II) from the solution to form a crystalline solid of greater purity with respect to the compound of Formula (II) than the solid dissolved in step (a), wherein the solvent comprises water.
18. The method of claim 17 , where step (a) is performed with an amorphous solid and wherein said solid of greater purity in step (b) is greater than about 95% pure with respect to the compound of Formula (II).